Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA).

Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and CSIS Senior Adviser, emphasized the breakdown of Section 101 and the urgent need for patent eligibility reform.

“Over the last fifteen years, the Supreme Court has steadily eroded the careful balance Congress established in the Patent Act of 1952. Beginning with Bilski v. Kappos in 2010 and continuing through Mayo v. Prometheus in 2012, Association for Molecular Pathology v. Myriad Genetics in 2013, and Alice Corp. v. CLS Bank in 2014, the Court took longexisting, but narrow, judicially-created exceptions to section 101—“abstract ideas,” “laws of nature,” and “natural phenomena”—and broadened them beyond recognition. Each of these cases, considered individually, appeared to resolve narrow disputes. Together, however, and especially as applied by the lower courts, they have produced a doctrine that is unpredictable, unworkable, and harmful to innovation.”

“The urgency of reform is underscored by the fact that, in all twelve judges sitting on the en banc Federal Circuit lamented the state of eligibility law, describing it as incoherent and unworkable.3 Their concerns have been echoed by witnesses and stakeholders from across industries, academia, and the innovation economy, who have testified to the chilling effect this uncertainty has on research, investment, and commercialization.”

Watch the full hearing here, and read Mr. Iancu’s opening remarks here.

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More

U.S. Universities: Engines of Economic Growth

By Sujai Shivakumar, Charles Wessner, Chris Borges, and Shruti Sharma Universities are among the United States’ most enduring sources of competitive advantage and a key pillar of the nation’s innovation system. Home to more than 35 of the world’s top 100 research universities, the United States owes many of its most
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More